Biotech companies have always licensed programs, but never so many from one region in particular.

Antibody-drug conjugates are rapidly expanding cancer therapies, with 19 approved globally and many more in development, but ...

Parabilis is set to receive $125m, including a $50m upfront payment and a $75m investment, subject to agreed conditions.

Developers extend the logic of ADCs and antibody conjugation, enabling highly selective therapeutics based on PROTACs, ...

Next Generation Drug Conjugates Market · GlobeNewswire Inc. Dublin, May 18, 2026 (GLOBE NEWSWIRE) -- The "Next Generation ...

Parabilis Medicines, the developer of drugs and antibody-drug conjugates targeting historically undruggable protein targets ...

Water-soluble polymers conjugated to proteins and anticancer drugs are in routine clinical use and clinical development as both single agents and components of combination therapy. This is ...

(MENAFN- GlobeNewsWire - Nasdaq) Key market opportunities for bispecific antibody drug conjugates (BsADCs) include their potential to revolutionize cancer treatment through enhanced tumor selectivity ...

The conjugate space is evolving fast - moving beyond traditional ADCs into new formats like degrader-conjugates, oligonucleotide conjugates, bispecific ADCs, and more. The 4 th Novel Conjugates Summit ...

Improved Linker and Payload Selection: The selection of suitable linkers and cytotoxic payloads greatly impacts ADC stability, efficacy, and safety. Next-generation ADCs aim to employ novel linkers ...

(MENAFN- GlobeNewsWire - Nasdaq) Key market opportunities for bispecific antibody drug conjugates (BsADCs) include their potential to revolutionize cancer treatment by targeting dual antigens, ...